On September 6, 2022 Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") reported the presentation of research across various types of cancer from its oncology portfolio and pipeline during the European Society for Medical Oncology (ESMO) (Free ESMO Whitepaper) Congress 2022, which is taking place virtually and in-person in Paris, France from September 9 to 13 (Press release, Eisai, SEP 6, 2022, View Source [SID1234619006]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A late-breaking oral presentation of detailed results from the LEAP (LEnvatinib And Pembrolizumab) clinical program including the final analysis of the Phase 3 LEAP-002 trial will be featured in a Proffered Paper session (NCT03713593(New Window); Presentation: #LBA34). The study evaluated the combination of lenvatinib plus anti-PD-1 antibody pembrolizumab from Merck & Co., Inc., Rahway, NJ, USA versus lenvatinib monotherapy as a first-line treatment for patients with unresectable hepatocellular carcinoma. Additionally, two mini-oral presentations will feature updated efficacy and safety data from the pivotal Phase 3 CLEAR (Study 307)/KEYNOTE-581 trial evaluating the combination in patients with advanced renal cell carcinoma (NCT02811861(New Window); Presentation: #1449MO) and Phase 3 Study 309/KEYNOTE-775 trial evaluating the combination in patients with advanced endometrial carcinoma (NCT03517449(New Window); Presentation: #525MO).

In addition, a new post-hoc analysis of three pivotal Phase 3 studies (Study 301/NCT00337103(New Window), Study 304/NCT02225470(New Window) and the EMBRACE trial/Study 305/NCT00388726(New Window)) evaluating the efficacy of eribulin (HALAVEN) versus other chemotherapies (capecitabine, vinorelbine and Treatment of Physician’s Choice [TPC], respectively) in patients living with metastatic breast cancer whose tumors have low or no HER2-expression will be presented during a poster session (Presentation: #259P).

"We look forward to presenting data at ESMO (Free ESMO Whitepaper), showcasing Eisai’s latest research on both lenvatinib and eribulin, with the goal of continuing to help people living with various types of cancer," said Dr. Takashi Owa, Chief Scientific Officer, Deep Human Biology Learning, Senior Vice President, Eisai Co., Ltd. "Presentations on the LEAP clinical program as well as new analyses for eribulin reinforce our commitment to the ongoing research of our portfolio in an effort to better serve patients and healthcare providers."

In March 2018, Eisai and Merck & Co., Inc., Rahway, NJ, USA (known as MSD outside the United States and Canada), through an affiliate, entered into a strategic collaboration for the worldwide co-development and co-commercialization of lenvatinib, both as monotherapy and in combination with pembrolizumab. To date, more than 15 trials have been initiated under the LEAP clinical program, which is evaluating the combination across multiple tumor types.

This release discusses investigational compounds and investigational uses for FDA-approved products. It is not intended to convey conclusions about efficacy and safety. There is no guarantee that any investigational compounds or investigational uses of FDA-approved products will successfully complete clinical development or gain FDA approval.

The full list of Eisai presentations is included below. All regular abstracts are available. All late-breaking abstracts will be made available Thursday, September 8, 2022, at 12:05 AM CEST.

Cancer Type Study Abstract Title Abstract Type & Details
LEAP clinical program
Gastrointestinal Cancers LEAP-002 Primary results from the phase 3 LEAP-002 study: lenvatinib plus pembrolizumab versus lenvatinib as first-line (1L) therapy for advanced hepatocellular carcinoma (aHCC)
Proffered Paper Session
Presentation #LBA34
September 10, 2022
8:30-8:40 AM CEST

Richard S. Finn, MD
Geffen School of Medicine, University of California, Los Angeles

LEAP-015 First-line lenvatinib (Len) + pembrolizumab (pembro) + chemotherapy vs. chemo in advanced/metastatic gastroesophageal adenocarcinoma: LEAP-015 safety run-in
Poster Session
Presentation #1223P
September 12, 2022
12:00-12:20 PM CEST

Kohei Shitara, MD
National Cancer Center Hospital East, Kashiwa, Japan

Genitourinary Cancer CLEAR (Study 307)/
KEYNOTE-581 Updated efficacy of lenvatinib (LEN) + pembrolizumab (PEMBRO) vs sunitinib (SUN) in patients (pts) with advanced renal cell carcinoma (aRCC) in the CLEAR study
Mini Oral Session
Presentation #1449MO
September 11, 2022
2:45-2:55 PM CEST

Camillo G. Porta, MD
Interdisciplinary Department of Medicine, University of Bari

Gynecologic Cancer Study 309/
KEYNOTE-775 Updated efficacy and safety of lenvatinib (LEN) + pembrolizumab (pembro) vs treatment of physician’s choice (TPC) in patients (pts) with advanced endometrial cancer (aEC): Study 309/KEYNOTE-775
Mini Oral Session
Presentation #525MO
September 11, 2022
4:30-4:35 PM CEST

Vicky Makker, MD
Medical Oncology, Memorial Sloan Kettering Cancer Center

Eribulin
Breast Cancer Study 301, Study 304 and EMBRACE trial/Study 305 Efficacy of eribulin mesylate in HER2-low metastatic breast cancer (MBC): results from three phase 3 studies
Poster Session
Presentation #259P
September 10, 2022
11:20-11:40 AM CEST

Peter A. Kaufman, MD
Division of Hematology and Oncology, University of Vermont Cancer Center